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INTRODUCTION
uman adenovirus (HAdV) is a linear, nonenveloped, double-stranded DNA virus that typically causes a mild respiratory, gastrointestinal, and
conjunctival illnesses in healthy persons.1 However,
HAdV may cause more severe infection in immunocompromised patients, especially those who have received
organ transplants. In kidney transplant recipients, urinary tract infection is the most frequently reported
manifestation at 4.8%, with rare dissemination.2,3 In
a surveillance study, 6.5% of kidney transplant recipients will have a positive polymerase chain reaction
(PCR) viremia within the ﬁrst year, without signiﬁcant
symptoms, that is self-limited.4 Disseminated HAdV,
deﬁned as symptomatic disease of multiple organ systems and associated viremia, is infrequently reported
and is associated with transplant rejection, failure,
and mortality.5–10 A case of disseminated HAdV in a
kidney transplant recipient is reported, including a
review of management and outcomes in disseminated
disease with the goal to guide clinical decision making.

H

CASE REPORT
A 45-year-old man with a history of end-stage kidney
disease, secondary to chronic reﬂux nephropathy,
received a deceased donor kidney transplant. Induction
immunosuppression comprised antithymocyte globulin and methylprednisolone. Maintenance therapy
included tacrolimus, mycophenolate mofetil, and
prednisone. His clinical course was complicated by
delayed allograft function that required ongoing hemodialysis for 4 weeks.
Kidney International Reports (2018) 3, 19–23

At his 6-week posttransplantation follow-up visit,
he reported a 2-day history of fever, fatigue, cough,
and hematuria. He was admitted to the hospital with
tachycardia, hypoxemia, and hypotension. He had
lymphopenia, thrombocytopenia, and a serum creatinine level of 1.73 mg/dl, compared to his baseline of
1.58 mg/dl. Urinalysis had sterile pyuria and hematuria. Computed tomography of his chest showed an
opacity consistent with pneumonia. Vancomycin,
piperacillintazobactam, and levoﬂoxacin were
empirically administered.
Over the next 3 days, he had nightly fevers. His
serum creatinine level increased to 2.4 mg/dl. Blood
cultures were negative. Studies for serum fungal–(1,3)B-D-glucan and Aspergillus galactomannan EIA, as
well as serum viral PCR cytomegalovirus and human
herpesvirus 6 infections, were negative. Urine BK viral
particles were not detected by PCR. A nasal swab was
positive for HAdV (PCR). Kidney ultrasound demonstrated a 12.6-cm allograft without evidence of renal
artery stenosis and with high resistive indices of the
upper pole. The 24-hour urine protein was 0.5 g/d at
admission and increased to 3.3 g/d by hospital day 7.
A biopsy was performed on the kidney allograft.
Parafﬁn sections showed an edematous parenchyma
with a histiocyte-predominant nodular inﬂammatory
inﬁltrate resembling granulomatous tubulointerstitial
nephritis. In place of the epithelioid histiocytes characteristic of granulomas, the predominant cell type in
the inﬁltrate was an atypical monocyte with an
eccentrically located, elongated, curved, and crinkled
nucleus. These cells inﬁltrated and distended the tubules, many of which contained epithelial cells with
19
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nuclear viral inclusions as well as apoptic cells
(Figure 1). Inﬂammation with rupture of the tubule
appeared to give rise to nodules that, in areas, coalesced
into solid inﬂammatory inﬁltrate. Remnants of the
ruptured tubular basement membranes could be found
within the pseudogranulomas on periodic acid–Schiff
staining. Strong nuclear staining for adenovirus antigen by cytopathic tubular epithelial cells conﬁrmed
adenovirus infection (Arkana Laboratories, Little Rock,
AR). No histologic features of acute T-cell or antibodymediated rejection were found, and the immunoﬂuorescence stain for complement factor C4d was negative.
Testing for serum and urine HAdV by PCR returned at
102,801 copies/ml and > 2,000,000 copies/ml,
respectively.
Initial treatment consisted of reduction of the
patient’s immunosuppression by discontinuing mycophenolate mofetil and targeting a serum tacrolimus
trough level of 3 to 7 ng/ml. The prednisone dose was
increased from 5 mg to 10 mg daily. Because of the
ongoing severity of his allograft dysfunction and
associated respiratory illness, he was given i.v. Ig
dosed at 0.5 g/kg for 2 days. Symptomatic improvement was reported by the second day after completion
of i.v. Ig. Serum creatinine and urine PCR HAdV DNA
levels declined steadily, with return to baseline and
resolution, respectively (Figure 2). The transplant team
was subsequently notiﬁed that the recipient of the
donor’s other kidney also developed disseminated
HAdV.

Figure 1. Kidney biopsy sample containing a virus-infected renal
tubule. Most of the renal tubular epithelial cells are lost or damaged
beyond recognition. Two of the residual epithelial cells contain
“smudged” intranuclear viral inclusions typical of adenovirus, with
nuclear enlargement and peripheral displacement of nuclear chromatin (black arrows). There is an associated intratubular and peritubular inﬁltrate consisting predominantly of distinct histiocytes with
elongated, curved, and crinkled nuclei (open blue arrows). Periodic
acid–Schiff stain, original magniﬁcation 600.
20
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Figure 2. Temporal trend of human adenovirus (HAdV) urine polymerase chain reaction (PCR), serum creatinine, and inception of
immunotherapy. Discontinuation of mycophenolate mofetil and
reduction of tacrolimus goal trough initiated at day 0, i.v. Ig 0.5 g/kg
received on days 8 and 9.

DISCUSSION
Kidney transplant recipients are at high risk over the
ﬁrst 6 months after transplantation for infectious
complications, with bacterial cystitis as 1 of the most
common culprits.11 HAdV is well recognized in the
healthy population to be associated with self-limited
respiratory, gastroenteritis, and conjunctivitis illness.
However, in kidney transplant recipients, the spectrum
of HAdV activity ranges from asymptomatic viremia to
hemorrhagic cystitis to allograft loss and mortality.1,4-10
In the largest case series to date following 349 kidney
transplant recipients over a 3-year period, the incidence of HAdV urinary infection and disseminated
disease was 4.8% and 3.1%, respectively. Onset of
disease was within the ﬁrst 3 months in 75% of the
patients, and 97% were reported within 1 year.3,12 A
10-year review of 170 kidney transplant recipients
reported an incidence of 4.7% for hemorrhagic cystitis
with median time to onset of 1 year.2 In comparison,
recipients postallogenic stem cell transplantation
have a median time of diagnosis of adenovirus hemorrhagic cystitis and dissemination within the ﬁrst few
weeks and month, respectively.13 Asymptomatic
HAdV viremia was reported as 6.5% from a surveillance study, over a 1-year period, of 92 kidney transplant recipients.4
HAdV in kidney transplant recipients may be
secondary to reactivation of latent disease, but infection also has been reported to be de novo from environmental sources or from endogenous transmission
through a donor organ.1,5 The most frequent signs and
symptoms at presentation include dysuria, fever,
hematuria, sterile (bacterial) pyuriam and acute kidney
injury.2,3,12,14 Given the lack of speciﬁcity, a broad
differential for the etiology of nephritis must be
maintained.15 Common extrakidney manifestations
Kidney International Reports (2018) 3, 19–23
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among kidney transplant recipients with disseminated
disease include orchitis, lymphopenia, gastroenteritis,
and pneumonitis.3,16-18 Conﬁrmatory diagnostic testing
is predominantly through HAdV PCR quantiﬁcation
and tissue biopsy histopathological assessments. Viral
culture may be conducted in some cases.12 PCR is
sensitive to all known serotypes of HAdV, and has the
beneﬁt of serial monitoring for response to treatment.
PCR testing for HAdV prognostication has been
reported in groups receiving hematopoietic stem cell
therapy and solid organ transplants.9,19,20
In the present case, this patient had a classically
deﬁned presentation of disseminated HAdV. His kidney biopsy ﬁndings of inclusion-bearing proximal
tubular cells and adjacent noncaseating granulomas in
the tubulointerstitium were consistent with HAdV

infection and conﬁrmed by immunohistochemical
staining.21 Given the severity of his acute kidney
injury and progressive pneumonia, he was treated with
i.v. Ig based on reports for hematopoietic stem cell
transplant recipients.19,22–24 Cidofovir was not used
because of concerns about additional nephrotoxicity in
the setting of severe acute kidney injury in the transplanted kidney.
Clinically symptomatic patients with HAdV viremia
and 2 or more organ systems involved is considered
disseminated disease. Little has been published about
clinical management, and current recommendations for
treatment are lacking.10,25 Overall, 29 cases of disseminated HAdV disease have been reported, including the
present case (Table 1). Adverse outcomes have been
reported in 6 cases (20%), including 4 deaths and 2

Table 1. Reported cases of disseminated adenovirus in patients post kidney transplantation

Year

Transplant
organ

Age (yr)/sex,
onset post
transplantation

Myerowitz (34)

1975

Kidney

2

Ardehali (35)

2001

3

Emovon (31)

4
5

Author
(reference)

1

Case no.

Additional
antiviral

Outcome

Unavailable, histological
conﬁrmation

None

Dead

Nephritis, pneumonitis,
gastritis, cardiac arrest

No PCR done, histological
conﬁrmation

None

Dead

46/F, 540 days

HC, nephritis, septic shock

No PCR, histopathology
conﬁrmation

RBV þ i.v. Ig

Alive, graft intact

Kidney

58/M, 22 days

Multiorgan failure, colitis

PCR: þblood, þstool

None; died prior to dx

Dead

Kidney

19/M, 12 yr

HC, pneumonia

PCR: þurine/no serum testing

CDV

Alive, graft intact

2007

Kidney

5/M, 65 days

HC, gastroenteritis

PCR: þurine, þserum

CDV

Alive, graft intact

2009

Kidney

51/F, 6 yr

Pneumonitis, diarrhea, HA, no
nephritis/HC

PCR: þurine, serum, stool,
BAL

CDV þ i.v. Ig

Alive, graft intact

Kidney

62/M, 29 days

PNA, colitis

PCR: urine, þserum, þstool

CDV þ i.v. Ig

Alive, graft intact

2009

Kidney

68/M, 14 days

HC, nephritis, severe sepsis
with respiratory compromise

PCR: þurine, þserum, CSF

CDV þ i.v. Ig

Alive, graft intact
Alive, graft loss

Organ or disease condition

Diagnostic testing

61/F, 40 days

Nephritis, pneumonitis,
leukopenia

Kidney

45/M, 6 yr

2003

Kidney-Pancreas

Rosario (36)

2006

Alsaad (37)

2007

6

Keswani (38)

7

Saquib (39)

Barraclough (26)

8
9
10

Gaspert (6)

2009

Kidney

64/M, 60 days

HC, nephritis, pneumonitis

PCR: þurine, þserum, þBAL

None

11

Kozlowski (5)

2010

Kidney

44/M, 20 days

HC, nephritis, pneumonitis

PCR: þBAL

GCV

Alive, graft loss

Watcharananan (3) 2011

Kidney

unkn

HC, nephritis

PCR: þserum

None

Alive, graft intact
Alive, graft intact

12
13

Kidney

unkn

HC, orchitis, diarrhea

PCR: þserum

CDV þ i.v. Ig

14

Kidney

unkn

HC, pneumonitis, orchitis

PCR: þserum

CDV

Dead

15

Kidney

unkn

HC, URI, orchitis

PCR: þserum

CDV

Alive, graft intact

16

Kidney

unkn

HC, orchitis, graft rejection

PCR: þserum

CDV þ i.v. Ig

Alive, graft intact

17

Kidney

unkn

HC, nephritis, enteritis

PCR: þserum

None

Alive, graft intact

18

Kidney

unkn

HC, nephritis enteritis

PCR: þserum

None

Alive, graft intact

19

Kidney

unkn

HC, leukopenia, enteritis

PCR: þserum

None

Alive, graft intact

57/M, 11 days

Fever, neutropenia/leukopenia,
nephritis

PCR: þserum

i.v. Ig

Alive, graft intact

20

Varma (20)

2011 Kidney-Pancrease

21

Sujeet (40)

2011

Kidney

65/F, 3 yr

HC, nephritis, enteritis,
respiratory symptoms

PCR: þserum

CDV

Alive, graft intact

22

Parasuraman (18)

2013

Kidney

44/M, 22 days

HC, nephritis, pneumonitis,
gastroenteritis

PCR: þurine, þserum

CDV, i.v. Ig

Alive, graft intact

23

Dawood (16)

2014

Kidney

70/F, 810 days

HC, nephritis, gastroenteritis

PCR: þurine, þserum, þstool

CDV, i.v. Ig

Alive, graft intact

Kidney

60/F, 28 days

HC, nephritis, gastroenteritis

PCR: þblood, þurine, þstool

CDV, i.v. Ig

Alive, graft intact

24
25

Lachiewicz (17)

2014

Kidney

20/F, 2 yr

Nephritis, URI

PCR: þurine, þserum

CDV, i.v. Ig

Alive, graft intact

26

Rady (41)

2014

Kidney

63/M, 42 days

HC, nephritis, gastroenteritis

PCR: þurine, serum not
performed

GCV, i.v. Ig

Alive, graft intact

27

Park (42)

2015

Kidney

32/F, 180 days

HC, nephritis, pneumonitis

PCR: þurine, þserum

RBV, i.v. Ig

Alive, graft intact

28

Index case

2016

Kidney

45/M, 42 days

HC, nephritis, pneumonitis

PCR: þurine, þserum

i.v. Ig

Alive, graft intact

29

Veer (43)

2017

Kidney

75/F, 365 days

HC, nephritis

PCR: þurine, þserum

i.v. Ig

Alive, graft intact

BAL, bronchoalveolar lavage; CSF, cerebrospinal ﬂuid; CDV, cidofovir; dx, diagnosis; F, female; GCV, ganciclovir; HA, headache; HC, hemorrhagic cystitis; M, male; PCR, polymerase
chain reaction; PNA, pneumonia; RBV, ribavirin; unkn, unknown; URI, upper respiratory infection; þ, positive; , negative.
Kidney International Reports (2018) 3, 19–23
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kidney allograft losses. In all, 21 case patients (72%)
received additional drug interventions along with
reduction of their immunosuppressive regimen. Cidofovir, used in 14 of 20 cases, was the most commonly
used antiviral agent, either alone or in combination
with i.v. Ig.
The ﬁrst step in standard-of-care for HAdV in
transplant recipients is reduction of the immunosuppressive regimen. This intervention is often effective at
resolving cases of hemorrhagic cystitis and
nephritis.3,14 The usual indication for additional therapies of antiviral or i.v. Ig is progressive disease despite
immunosuppression reduction.3,26 A PCR quantiﬁcation of 1 log reduction within 2 to 3 weeks is considered a therapeutic response.19 Antiviral therapies in
kidney transplant recipients include cidofovir, ganciclovir, ribavirin, and brincidofovir and i.v. Ig.27,28
Cidofovir, the most commonly used antiviral agent,
with activity against all serotypes of HAdV, is a
cytosine purine analogue that leads to chain termination.27,28 The primary adverse effect is hematological as
well as kidney toxicity.29 Cidofovir is not considered a
preferred therapy in kidney transplant recipients
owing to clearance by the kidney and risk of nephrotoxicity. Brincidofovir (formally CMX101) is a new
lipid derivative of cidofovir. The lipid formulation allows increased intracellular penetration that minimizes
proximal tubular accumulation, and as such, may
reduce the risk of nephrotoxicity.28 The AdVise Study
(NCT02087306), a currently completed phase III trial, is
predominantly a study of hematopoietic stem cell recipients with small subset of solid organ transplant
recipients, evaluating brincidofovir for HAdV disease.
Results are expected to be reported soon.28,30 Ganciclovir, a 1-phoshorylated purine analog, has limited
effectiveness in HAdV, but there are case reports of its
use.2,4,28 Ribavirin, a nucleoside analogue of guanosine,
is also not generally recommended due to in vitro activity against only subgroup C of HAdV. However, in
the posttransplantation population, subgroup C is a
common cause of disease.1,27,31 Intravenous Ig is proposed to promote antiviral activity or to provide passive immunotherapy.32,33 Intravenous Ig has been used
in combination with cidofovir or as a single agent.
In conclusion, in kidney transplant recipients, HAdV
is an uncommonly recognized, but potentially serious,
infectious complication. This case reafﬁrms the clinical
context in which to consider such a viral source of
infection in kidney transplant recipients. We report
the successful management of disseminated HAdV with
i.v. Ig as a single agent along with reduction of immunosuppressive therapy. Ongoing prospective studies of
HAdV surveillance and antiviral strategies are needed to
improve outcomes in this high-risk group.
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